In the middle of our Zoom interview, Mati Gill, Tel Aviv-based CEO of venture studio AION Labs, excused himself calmly to find shelter when a
Plus Phase II data on ABION’s MET tyrosine kinase inhibitor, and 60 Degrees Pharmaceuticals giving up on repurposing its antimalarial drug for Covid-19. Harmony Biosciences’
Sanofi’s anti-OX40L antibody, amlitelimab, passed a 390-patient Phase IIb trial by hitting the primary endpoint, with patients seeing up to a 61.5% improvement on a
In a first look at Amgen’s experimental PRMT5 inhibitor, roughly 16% of patients with various cancers saw their tumors shrink by at least 30%, equating
The European Medicines Agency rejected on Friday an appeal from Amylyx Pharmaceuticals to reconsider a negative review opinion for its ALS drug Relyvrio, further dimming
Pfizer has secured an FDA approval for etrasimod in moderate to severe ulcerative colitis. It’s the second sphingosine-1-phosphate (S1P) drug to arrive on the UC
After a patient died while waiting for care in an emergency department waiting room in Washington state, the woman’s husband has filed suit against the
The PREDICT prognostication tool was able to estimate overall survival (OS) with decent accuracy in a large independent U.S. dataset of breast cancer patients, researchers
HONOLULU — Use of tobacco, cannabis, or both increased among U.S. youths, according to 2021-2022 data from the CDC’s National Youth Tobacco Survey (NYTS). In
Two newer approaches to management of major hemorrhage missed the mark in randomized clinical trials published in a special transfusion-related issue of JAMA. In the